ATM gene mutation
Clinical trials for ATM gene mutation explained in plain language.
Never miss a new study
Get alerted when new ATM gene mutation trials appear
Sign up with your email to follow new studies for ATM gene mutation, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo targets tough cancers in early trial
Disease control OngoingThis early-phase study tests a combination of two oral drugs, olaparib and ASTX727, in adults with advanced solid tumors that have mutations in genes like BRCA1, BRCA2, PALB2, ATM, or CHEK2. The main goals are to find the safest dose and to check for side effects. About 18 partic…
Matched conditions: ATM GENE MUTATION
Phase 1 • Sponsor: Varun Monga, MBBS • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Cancer drug targets BRCA mutations beyond breast and ovarian
Disease control OngoingThis phase 2 trial tests the drug talazoparib in 150 people with advanced cancers that have not responded to standard treatments. Participants must have specific gene changes in BRCA1, BRCA2, or related DNA repair genes. The drug works by blocking an enzyme that helps cancer cell…
Matched conditions: ATM GENE MUTATION
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Targeted drug olaparib tested in breast cancer patients with DNA repair flaws
Disease control OngoingThis phase 2 study tests the drug olaparib in 114 people with metastatic breast cancer whose tumors have mutations in certain DNA repair genes (like BRCA1, BRCA2, ATM, PALB2, and others). Olaparib is a PARP inhibitor that may kill cancer cells by blocking their ability to fix dam…
Matched conditions: ATM GENE MUTATION
Phase 2 • Sponsor: Beth Israel Deaconess Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC